W. Robert Lee, MD, on Prostate Cancer: Results of the NRG Oncology RTOG 0415 Study

W. Robert Lee, MD, of Duke University, discusses this phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer (Abstract 1).

Related Videos

Kidney Cancer

Toni Choueiri, MD

Toni Choueiri, MD: Renal Cancer Update

Toni Choueiri, MD, of the Dana-Farber Cancer Institute, summarizes key points from a session he chaired on clear and non-clear cell renal cancer, including information on molecular...

Solid Tumors

Christopher J. Sweeney, MBBS

Christopher J. Sweeney, MBBS: Testicular Cancer Update

Christopher J. Sweeney, MBBS, of the Dana-Farber Cancer Institute, reviews important presentations on testicular cancer, including dose intensification for first-line therapy of me...

Prostate Cancer

Fred Saad, MD

Fred Saad, MD, on Prostate Cancer: The Year in Review

Fred Saad, MD, of the University of Montreal, summarizes his session on the latest treatment developments in prostate cancer, including the role of chemotherapy in hormone-sensitiv...

Prostate Cancer

Paul L. Nguyen, MD

Paul L. Nguyen, MD, on Prostate Cancer: Results of the NRG Oncology/RTOG 9601 Study

Paul L. Nguyen, MD, of Dana-Farber Cancer Institute, discusses this phase III trial in which prostate cancer patients were given antiandrogen therapy with bicalutamide during and a...

Solid Tumors

Matthew Smith, MD, PhD

Matthew Smith, MD, PhD, on Bone Metastases: Treatment Update

Matthew Smith, MD, PhD, of the Massachusetts General Hospital Cancer Center, discusses the best use of approved therapies for tumors that have spread to the bone.